Show simple item record

dc.contributor.authorGuo, Q.
dc.contributor.authorWang, Y.
dc.contributor.authorXu, Daniel
dc.contributor.authorNossent, J.
dc.contributor.authorPavlos, N.
dc.contributor.authorXu, J.
dc.identifier.citationGuo, Q. and Wang, Y. and Xu, D. and Nossent, J. and Pavlos, N. and Xu, J. 2018. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Research. 6: Article ID

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our  understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA.

dc.titleRheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.
dc.typeJournal Article
dcterms.source.titleBone Research
curtin.departmentSchool of Public Health
curtin.accessStatusOpen access

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as